A phase 3 clinical trial published in the New England Journal of Medicine found that combining pembrolizumab with belzutifan improved disease-free survival in patients with resected clear-cell renal-cell carcinoma, though the combination also carried a higher rate of serious adverse events.
What the Trial Found
The New England Journal of Medicine has published findings from the LITESPARK-022 phase 3 trial, a study examining treatment options for patients with clear-cell renal-cell carcinoma — the most common form of kidney cancer — who had already undergone surgical removal of their tumour.
The trial compared two approaches: pembrolizumab alone, which is an established immunotherapy drug, against pembrolizumab combined with belzutifan, a newer targeted therapy. The data shows that patients receiving the combination treatment achieved higher disease-free survival rates than those on pembrolizumab alone.
That’s a meaningful distinction. Disease-free survival measures how long a patient lives after treatment without their cancer returning — so a higher rate in this category suggests the combination may be more effective at keeping the disease at bay after surgery.
The Trade-Off: More Benefit, More Risk
But the findings come with an important caveat. Patients on the combination therapy also faced an increased risk of grade 3 or higher adverse events — medical shorthand for serious side effects that are severe enough to require medical intervention or hospitalisation. The trial did not eliminate that risk by adding a second drug; it appears to have increased it.
This kind of trade-off is common in oncology research. More aggressive treatment combinations often produce better outcomes on survival measures, but the question for clinicians and patients is whether the additional benefit justifies the additional burden of side effects. The LITESPARK-022 results, according to the journal’s reporting, suggest the combination performs better on the primary measure of disease-free survival — but the side effect profile warrants careful consideration in treatment planning.
Understanding the Drugs Involved
Pembrolizumab — sold under the brand name Keytruda — works by helping the immune system identify and attack cancer cells. It’s already approved for a range of cancers in the UK. Belzutifan is a HIF-2α inhibitor, a type of drug that blocks a protein involved in tumour growth, and has been the subject of growing research interest in kidney cancer treatment.
The LITESPARK-022 trial represents phase 3 testing, which is the stage of clinical research that directly compares a new treatment against an existing standard of care in a large patient group before regulatory bodies consider approval.
—
Source: @NEJM
Key Takeaways
- Combining pembrolizumab with belzutifan produced higher disease-free survival than pembrolizumab alone in patients with resected clear-cell renal-cell carcinoma, according to the LITESPARK-022 phase 3 trial
- The combination therapy was associated with an increased risk of grade 3 or higher adverse events — serious side effects requiring medical management
- The findings were published by the New England Journal of Medicine and covered in a Quick Take video summary issued by the journal’s official account
What This Means for Kent Residents
Kidney cancer affects thousands of people across the UK each year, and Kent residents being treated for or recovering from renal-cell carcinoma may wish to discuss these emerging findings with their oncologist or specialist through their local NHS trust or via NHS Kent and Medway ICB. This trial does not change current treatment guidelines — only regulatory approval by bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) can do that — but it adds to the evidence base that clinicians will draw on when reviewing options. If you have concerns about kidney cancer symptoms, treatment, or recovery, contact your GP in the first instance or call NHS 111 for non-emergency medical advice; in an emergency, always call 999.